Accelerate Diagnostics, INC

Accelerate Diagnostics, Inc. has consummated the sale of certain assets to Indaba Capital Management and confirmed its Chapter 11 liquidation plan, resulting in the cancellation of all outstanding common stock and warrants with no recovery for equity holders.

Accelerate Diagnostics, Inc. has entered into a definitive agreement to sell substantially all of its assets to Indaba Starling, LLC, an affiliate of its secured noteholder, as part of its ongoing Chapter 11 bankruptcy proceedings, with common stockholders expected to face significant or complete loss.

Accelerate Diagnostics, Inc. announced that Chief Financial Officer David Patience will resign effective June 30, 2025, to pursue other professional opportunities.

Accelerate Diagnostics, Inc. is set to be delisted from the Nasdaq Stock Market due to its recent Chapter 11 bankruptcy filing and failure to meet minimum bid price and market value requirements.

Accelerate Diagnostics has voluntarily initiated Chapter 11 proceedings and agreed to terms with Indaba Capital Management for the sale of substantially all of its assets.

Accelerate Diagnostics, Inc. has entered into a retention bonus agreement with its President and CEO, Jack Phillips, providing him with a $200,000 bonus.

Accelerate Diagnostics reported its third quarter 2024 results, showing a decrease in net sales and a net loss, while also announcing a strategic review process.

Accelerate Diagnostics reports a net loss of $25.8 million for the first half of 2024, highlighting ongoing financial challenges and the need for additional funding.

Accelerate Diagnostics reported a net loss of $14.2 million for the first quarter of 2024, while navigating ongoing financial challenges and focusing on product development.

Accelerate Diagnostics files an amendment to its 2024 annual report to include previously omitted information regarding directors, executive compensation, security ownership, related transactions, and principal accountant fees.

Accelerate Diagnostics' 10-K filing reveals substantial doubt about its ability to continue as a going concern due to recurring losses and significant debt, prompting a strategic review.

Accelerate Diagnostics, Inc. outlines the details of its registered common stock and preferred stock, including voting rights, dividend entitlements, and anti-takeover provisions, as of December 31, 2023.

CEO Jack Phillips of Accelerate Diagnostics reports the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.

Larry Michael Mertz, Chief Technology Officer of Accelerate Diagnostics, sold shares to cover tax withholding obligations related to vesting restricted stock units.

Chief Financial Officer of Accelerate Diagnostics, David Patience, reports the acquisition and disposal of company stock and restricted stock units on April 1, 2025.

David Patience, CFO of Accelerate Diagnostics, reports the acquisition and disposal of common stock and restricted stock units to cover tax obligations.

CEO Jack Phillips of Accelerate Diagnostics reports the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.

Director John Patience of Accelerate Diagnostics, Inc. purchased 200,000 shares of common stock in a private transaction on December 3, 2024.

Accelerate Diagnostics is holding its 2024 Annual Meeting of Shareholders on May 7, 2024, to vote on the election of directors, ratification of Ernst & Young LLP as the independent auditor, and an amendment to the 2022 Omnibus Equity Incentive Plan.

Accelerate Diagnostics is offering 4,500,000 units and pre-funded units, each including common stock or pre-funded warrants and warrants, to raise capital for its Wave program and general corporate purposes.

Accelerate Diagnostics plans to offer 4,500,000 units, each with a share of common stock and a warrant, along with pre-funded units for certain investors.

Indaba Capital Management, L.P. has increased its stake in Accelerate Diagnostics, Inc.'s convertible notes, gaining majority control and significant influence over key debt-related decisions.

Armistice Capital, LLC and Steven Boyd have disclosed a 7.45% passive ownership stake in Accelerate Diagnostics, Inc., holding 1,879,227 shares of common stock.

Armistice Capital, LLC and Steven Boyd have disclosed a beneficial ownership of 8.25% in Accelerate Diagnostics, Inc., totaling 2,078,000 shares of common stock.

Griffin Asset Management, LLC has filed an amended Schedule 13G, reporting a 4.0% passive beneficial ownership stake in Accelerate Diagnostics, Inc. as of December 31, 2024.